Monopar Therapeutics MNPR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's return on equity?
- Monopar Therapeutics (MNPR) reported return on equity of -15.9% in Q1 2026.
- How has Monopar Therapeutics's return on equity changed year-over-year?
- Monopar Therapeutics's return on equity increased by 70.8% year-over-year, from -54.3% to -15.9%.
- What is the long-term trend for Monopar Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Monopar Therapeutics's return on equity has grown at a -20.4% compound annual growth rate (CAGR), from -44.5% to -14.2%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.